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ABSTRACT 
 
Emerging evidence supports an important role for T cells in the genesis of hypertension. 
Because this work has predominantly been performed in experimental animals, we sought to 
determine whether human T cells are activated in hypertension. We employed a humanized 
mouse model in which the murine immune system is replaced by the human immune system. 
Angiotensin II increased systolic pressure to 162 mm Hg vs. 116 mm Hg for sham treated 
animals. Flow cytometry of thoracic lymph nodes, thoracic aorta and kidney revealed 
increased infiltration of human leukocytes (CD45+) and T lymphocytes (CD3+ and CD4+) in 
response to angiotensin II infusion. Interestingly, there was also an increase in the memory T 
cells (CD3+/CD45RO+) in the aortas and lymph nodes. Prevention of hypertension using 
hydralazine and hydrochlorothiazide prevented the accumulation of T cells in these tissues. 
Studies of isolated human T cells and monocytes indicated that angiotensin II had no direct 
effect on cytokine production by T cells or the ability of dendritic cells to drive T cell 
proliferation. We also observed an increase in circulating IL-17A producing CD4+ T cells and 
both CD4+ and CD8+ T cells that produce IFN-γ in hypertensive compared to normotensive 
humans.  Thus, human T cells become activated and invade critical end-organ tissues in 
response to hypertension in a humanized mouse model. This response likely reflects the 
hypertensive milieu encountered in vivo and is not a direct effect of the hormone angiotensin II.  
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INTRODUCTION 
In the past several years it has become evident that inflammation contributes to the elevation 
of blood pressure and end organ damage in numerous experimental models of hypertension. 
In mice lacking the recombinase-activating gene (RAG-1-/- mice), which lack all lymphocytes, 
the hypertensive responses to angiotensin II (ang II), deoxycorticosterone acetate-salt 
challenge, norepinephrine and emotional stress are blunted.1-3 Moreover, these mice are 
protected against endothelial dysfunction, vascular hypertrophy and do not develop an 
increase in vascular superoxide as observed in normal mice. Adoptive transfer of T cells, but 
not B cells, restores the hypertensive response and vascular dysfunction in RAG-1-/- mice.1 
Mice with severe combined immunodeficiency are also protected against hypertension.4 
Likewise, deletion of the RAG-1 gene in Dahl salt-sensitive rats blunts their hypertension and 
renal damage upon salt feeding.5 T cells with an effector phenotype infiltrate the kidney and 
periadventitial tissues, where they release inflammatory cytokines, including interleukin 17A, 
interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α) that in turn alter renal and vascular 
function and participate in end-organ damage.6-8 Genetic deletion of these cytokines or 
treatment with their specific antagonists blunts hypertension and its attendant end-organ 
dysfunction.  
Despite the overwhelming evidence that inflammation and immunity contribute to hypertension 
in these experimental models, there is a paucity of information to suggest that hypertension or 
the factors present in the hypertensive milieu lead to T cell activation in humans. In the present 
study, we addressed this issue using several approaches. First we used a unique animal 
model, the bone/liver/thymus (BLT) humanized mouse to determine whether Ang II-induced 
hypertension is associated with T cell activation and infiltration into key target tissues. Second, 
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we examined the direct effects of ang II on human T cell activation and human dendritic cell 
(DC) function in culture. Finally, we analyzed the phenotype of circulating T cells in humans 
with and without hypertension.   
 5
METHODS 
BLT mice: The Vanderbilt University Institutional Animal Care approved all experiments. Mice 
were cared for in accordance with the Guide for the Care and Use of Laboratory Animals. 
Bone marrow, liver, thymus (BLT) mice were produced on a NSG (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ) background as previously described.9, 10 Twelve to fourteen weeks after immune 
reconstitution, osmotic minipumps (Alzet, model 2002) were implanted subcutaneously for 
infusion of either ang II (490 ng/kg/min) or an isotonic vehicle (sodium chloride/acetic acid 
solution) for sham mice. In some experiments, hypertension was prevented by co-
administration of hydralazine and hydrochlorothiazide as previously described.11  
Response of human T cells and dendritic cells to ang II: Two experimental approaches 
were employed to examine the direct effects of ang II on human immune cells. In the first, 
human T cells were isolated from the blood of normotensive volunteers using magnetic sorting 
and 106 cells were exposed to anti-CD3+ coated culture plates with anti-CD28 (2 μg/ml) added 
to the media for 3 days in the presence or absence of 0.1 μMol/L of ang II. Intracellular staining 
was employed to identify cells containing IFN-γ, IL-17A and forkhead box P3 (FoxP3) as 
previously described.12 As a second approach, human monocytes were differentiated to 
dendritic cells in the presence of GM-CSF and IL-4 with and without addition of 0.1 μMol/L ang 
II. These cells were then co-cultured with CFSE-labeled T cells from the same volunteer at a 
ratio of 1 dendritic cell to 10 T cells.    
Studies of circulating T cells in humans: Peripheral blood samples were collected in 
ethylenediaminetetraacetic acid (EDTA) from 20 hypertensive patients and 20 healthy 
volunteers, matched for age, sex and BMI.  A detailed history of major cardiovascular risk 
factors for atherosclerosis and characteristics of hypertension were obtained (Table 1). Patient 
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groups did not differ in major cardiovascular risk factors apart from hypertension. Exclusion 
criteria are listed in the supplementary materials and methods. Office blood pressure was 
determined in all subjects and 4 resting measurements were averaged. Twenty-four hour 
ambulatory blood pressures were used to confirm hypertension. The Local Research Ethics 
Committee of Institute of Cardiology at Jagiellonian University approved collection of tissue 
specimens and all patients gave written informed consent.  
Flow cytometry: Flow cytometry was performed on single cell suspensions of thoracic lymph 
nodes, the right kidney and the descending thoracic aorta as previously described.12 Human 
cells were initially identified by anti-human CD45 and subsets were identified using antibodies 
that specifically react with human cells. Preliminary studies showed that these antibodies did 
not identify cells in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice without immune reconstitution. Flow 
cytometry gates were established using flow minus one as previously described and employed 
in our laboratory (Figure S1).13, 14 
Statistics: Data in the manuscript are presented as mean ± standard error of the mean. To 
compare blood pressure measurements in mice over time, two-way ANOVA with multiple 
comparisons was employed. To compare numbers of human T cells in various tissues we used 
either an unpaired T test to analyze or the non-parametric Mann Whitney test when variances 
between groups were not equal. To show the effect of hypertension on myeloid differentiation, 
we used one-way ANOVA to analyze the flow cytometry data. For comparison of the frequency 
of T cell subtypes in humans, unpaired T tests were employed with a Bonferroni correction. Chi 
square analysis with Bonferonni correction was employed to compare the frequency of risk 
factors between the normotensive and hypertensive populations. P values reported in the 
figures and tables represent the adjusted values after multiple testing.  
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Please see the on-line supplement for complete description of the methods employed. 
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RESULTS 
Effect of angiotensin II-infusion on blood pressure of humanized mice: The blood 
pressure of humanized mice increased to 162 mmHg following two weeks of ang II infusion 
when compared to mice that were exposed to a sham infusion (Figure S2). Co-administration 
of hydralazine and hydrochlorothiazide reduced blood pressure to 112 ± 0.5 mmHg.  
Effect of angiotensin II-induced hypertension on the presence of human T cells in the 
kidney: Following 2 weeks of ang II or sham infusion, flow cytometry was performed to 
quantify the presence of T cell activation in the kidney that had not previously undergone the 
thymus/liver transplant. As shown in the representative flow cytometry dot plots in figures 1A-C 
and the mean data in figures 1D-G, there was accumulation of total human leukocytes (CD45+ 
cells), total T cells (CD3+) and several T cell subpopulations (CD4+ and CD8+) in the kidney. 
The cells were predominantly composed of CD4+ T cells. There was a non-significant trend for 
an increase in CD8+ T cells. Among the CD3+ and CD4+ T cells, ang II infusion increased the 
number of renal CD45RO+ cells indicating an increase in human memory T cells (Table 2). 
There were relatively few CD69+ T cells in the kidney and these were not changed by ang II 
infusion (Table S1). Prevention of hypertension by co-administration of hydrochlorothiazide 
and hydralazine completely abrogated the elevation of both CD4+ and CD8+ T cells and the 
formation of RO+ cells in the kidney (Figure 1 and table 2).  
Effect of angiotensin II-induced hypertension on the presence of human T cells in the 
aorta: Representative flow cytometry for human T cells in the aorta is shown in Figure 2A-C. In 
contrast to the kidney, relatively few human cells accumulated in the aorta; however, ang II 
infusion increased the small numbers of human CD45+ and CD3+, and CD4+ and CD8+ T cells 
(Figure 2D-G) in the aorta compared to sham infusion. Total CD45RO+ memory T cells and 
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CD4+ memory T cells in the aorta were likewise increased by ang II infusion (table 2). 
Prevention of hypertension with hydralazine and hydrochlorothiazide significantly reduced 
accumulation of CD3+ and CD8+ T cells in the aorta and reduced the presence of total memory 
T cells and CD4+ memory T cells. (Figure 2 and table 2). Ang II did not change the few CD69+ 
T cells in the aorta (Table S1). 
Effect of angiotensin II induced hypertension on the presence of human T cells in lymph 
nodes: The greatest accumulation of human cells observed in the humanized mice was noted 
in lymph nodes. Representative flow cytometry dot plots are shown in Figure 3A-C. Ang II-
induced hypertension caused a 3 to 5-fold increase in human CD3+, CD4+ and CD8+ T cells in 
the murine lymph nodes of this model (Figure 3D-G). Ang II also caused a striking increase in 
the memory CD3+, CD4+ and CD8+/CD45RO+ T cells in the lymph nodes (Table 2). As in the 
cases of the kidney and aorta, prevention of hypertension abolished the accumulation of total 
CD3+ cells and both CD4+ and CD8+ T cells (Figure 3 and table 2). Unlike the case of the 
kidney and aorta, treatment with hydralazine and hydrochlorothiazide paradoxically increased 
the number of total CD45RO+ memory T cells and CD4+ memory T cells in lymph nodes.  
Myeloid differentiation in angiotensin II treated humanized mice: Because of limitations of 
fluorochromes in our flow cytometry, we were unable to stain for monocyte/macrophages or 
dendritic cells in the same animals in which we examined T cell populations; however, one can 
approximate non-T cell populations by subtracting the CD3+ population from CD45+ cells. 
There were non-significant trends for increases in these cells in the kidney (Figure 4A) and the 
aorta (Figure 4B). In the lymph nodes, ang II infusion caused a significant increase in this 
population of human cells (Figure 4C). In one animal, there was a striking increase in the 
number of CD45+/CD3- cells (Figure 4C); however, a significant difference remained between 
sham and ang II infused mice even after exclusion of this animal. In selected mice, we 
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examined staining for CD14, a marker of human monocytes and CD83, an activation marker 
that appears on monocyte-derived dendritic cells (Figure 4D-E). There were relatively few of 
these human myeloid cells in the kidney of ang II-infused humanized mice, and these were 
equally distributed between CD14+, CD14+/CD83+ and CD14-/CD83+ cells. In contrast, in the 
aorta and lymph nodes, the predominant population of human myeloid cells was CD83+/CD14-.  
Direct effects of ang II on human T cells and dendritic cell function: Our above data 
suggest that normalizing blood pressure prevents human T cell activation in vivo, suggesting 
that ang II does not directly stimulate T cell cytokine production. One criticism of these 
experiments is that the anti-hypertensive drugs might have off-target effects to inhibit T cell 
activation. To further study the direct effect of ang II on human immune cells, we performed 
two additional experiments. In the first, we analyzed the effect of ang II (0.1 μMol/L) on the 
production of IL-17A, IFN-γ, FoxP3 and TNF-α in human T cells cultured for 7 days on anti-
CD3 plates using intracellular staining. As shown in figures 5A – 5D, there was no direct effect 
of ang II on the production of TH1 cytokines or FoxP3 by CD3+, CD4+ or CD8+ T cells. Because 
murine T cells can produce ang II,15 we considered the hypothesis that endogenous ang II 
might affect human T cell production of cytokines. Co-incubation human T cells with ramipril (1 
μMol/L), however, had no effect on production of any cytokines measured (data not shown). In 
another experiment, we cultured human monocytes for 7 days with granulocyte/macrophage 
colony stimulating factor (GM-CSF) and IL-4 in the presence and absence of ang II (0.1 
μMol/L). The resultant differentiated dendritic cells were then cultured with CFSE- labeled T 
cells from the same donor. As shown in figure 5E and S3, there was no effect of ang II on the 
ability of human DCs to drive T cell proliferation. Moreover, ang II did not directly stimulate the 
accumulation of isoketal-protein adducts in human DCs, as evidenced by intracellular staining 
with the isoketal adduct antibody D11 (Figure 5F).  
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Inflammatory profile of circulating T cells in humans with and without hypertension: To 
further characterize the effect of hypertension on T cell phenotype, we studied 20 
normotensive and 20 hypertensive humans, matched for sex, age and BMI. Hypertensive 
patients had significantly higher office blood pressures and both systolic and diastolic blood 
pressures as measured by ambulatory blood pressure monitoring. Plasma renin and 
aldosterone levels were elevated in the hypertensive group compared to the normotensive 
subjects. As shown in figure 6A and 6B, the percent of both CD4+ and CD8+/CD45RO+ 
circulating T cells was greater in the hypertensive patients than in the normotensive controls. 
Intracellular staining showed that CD4+ T cells of humans with hypertension produce greater 
amounts of IL-17A than normotensive controls (Figure 6C and D). Very few circulating CD8+ T 
cells were positive for IL-17A (data not shown). Intracellular staining for IFN-γ and TNFα 
revealed that both of these cytokines were increased in CD4+ T cells and CD8+ T cells of 
humans with hypertension and were commonly co-produced within the same cells (Figure 6E 
and 6F).  
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DISCUSSION 
The major finding of the current study is that the hypertensive stimulus of ang II promotes 
accumulation of human T cells in the kidney, aorta and lymph nodes of humanized mice. 
These cells exhibit an increase in the memory cell marker CD45RO and to a lesser extent the 
activation marker CD69. In addition, CD3- CD45+ cells, which represent other myeloid cells, 
are increased in lymph nodes by ang II infusion. There also appears to be differentiation of 
human monocytes to activated DCs in hypertensive mice. Finally, we demonstrate that 
circulating T cells of humans with hypertension exhibit evidence of activation, as indicated by 
an increased percent of memory T cells and an increase in production of IL-17A and IFN-γ.  
While substantial data support the role of T cells in the genesis of experimental hypertension, 
there is a paucity of data showing that these cells are activated as a result of human 
hypertension. Many years ago, Olsen noted periarteriolar infiltration of immune cells in humans 
with hypertension, and pointed out that these appeared to be lymphocytes and monocytes.16 
We found that blood levels of IL-17A are three-times higher in diabetic humans with 
hypertension as compared to those without hypertension.6 Herrera et al showed that the T cell 
suppressing agent mycophenolate mofetil lowers blood pressure in humans with rheumatoid 
arthritis or psoriasis.17 Recently, Yoshida et al demonstrated that the TNF-α antagonist 
infliximab lowers blood pressure in patients with rheumatoid arthritis.18 Of note, the incidence 
of hypertension is increased in humans with such autoimmune diseases.19, 20 Youn et al 
showed that humans with hypertension have an increased number of circulating 
immunosenescent pro-inflammatory CD8+ T cells compared to age-matched non-hypertensive 
subjects.21 These cells produced increased amounts of IFN-γ, TNF-α and the cytotoxic 
molecules granzyme B and perforin than CD8+ T cells from normal subjects. 
Immunohistochemical studies of renal biopsies revealed an increase in both CD4+ and CD8+ T 
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cells in humans with hypertensive nephrosclerosis compared to controls. These authors also 
observed an increase of CXCR3 cytokines in the sera of hypertensive patients.  
Our current studies of circulating T cells from humans with hypertension confirm the findings of 
Youn et al that CD8+ T cells produce large amounts of TNFα and IFN-γ. We also found that 
CD4+ T cells of hypertensive humans produce increased amounts of IL-17A and IFN-γ. The 
increased number of TH17 cells is compatible with our prior finding that humans with 
hypertension and diabetes have higher circulating levels of IL-17A than patients with diabetes 
alone.6 In the present study, we also found an increase in the percent of circulation memory 
CD4+ and CD8+ T cells. We recently showed that memory T cells are major sources of IFN-γ 
and IL-17A in mice with hypertension, and that these cells seem to prime hypertensive 
responses to repeated challenges with high salt or ang II.22 Thus, the finding of increased 
circulating memory cells might have pathophysiological significance for sustaining 
hypertension in humans.  
The accumulation of human T cells in the kidney of humanized mice is similar to the 
accumulation of renal T cells observed by Youn et al and parallels similar increases that we 
and others have observed in mice with experimental hypertension.21, 23, 24 It is likely that 
cytokines released from T cells in the kidney promote sodium and volume retention and lead to 
renal damage. We recently found that IFN-γ modulates phosphorylation and activation of the 
Na-K-2Cl cotransporter, Na-Cl cotransporter, and Ste20/SPS-1-related proline-alanine-rich 
kinase in response to long-term ang II infusion.25 In this study, we established an important 
role of IL-17A and IFN-γ in modulating expression of Na/H-exchanger isoform 3 and the motor 
myosin VI in the proximal tubule and in the anti-natriuretic and anti-diuretic effects of ang II. 
The propensity of human T cells to accumulate in the kidney supports the notion that these 
cells might contribute to human hypertension in a similar fashion.  
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It is also of interest that we observed a striking increase in human T cells in the thoracic lymph 
nodes of the humanized mice in response to ang II infusion. This was paralleled by an 
increase in cells bearing the memory cell marker CD45RO. Memory cells persist after an initial 
expansion of a naïve pool, and it is therefore logical to conclude that the increase in total T 
cells and memory T cells in the lymph nodes was due to proliferation and expansion in 
response to ang II infusion not observed in the sham infused mice. We cannot exclude the role 
of chemokines and adhesion molecules that might also have been increased by ang II in the 
lymph nodes and kidneys of the humanized mice that could have attracted the human cells to 
these organs. It is notable that while prevention of hypertension using hydralazine and 
hydrochlorothiazide reduced the total number of T cells in the lymph nodes, the number of 
memory T cells in the lymph nodes increased. This might reflect differences in the effect of 
hypertension as well as direct effects of angiotensin II on trafficking of memory cells in 
secondary lymphoid organs.  
Using strict flow minus one gating criteria, we also observed an increase in CD3+ cells lacking 
either CD4 or CD8 surface markers, particularly in the lymph nodes. We have observed a 
similar increase in double negative murine T cells in hypertensive mice. It is conceivable that 
these double negative T cells are actually CD4+ cells that have lost surface CD4, as has been 
observed during intense T cell stimulation with phorbol esters or myxoma virus.26, 27 
We have previously proposed that mild elevations in blood pressure, such as observed in pre-
hypertension, lead to formation of neoantigens that activate T cells which exacerbate vascular 
remodeling and renal dysfunction, leading to further elevations of blood pressure.28 Our current 
finding that preventing the initial elevation in blood pressure prevents human T cell activation is 
in keeping with this concept. Our results also indicate that ang II does not directly activate 
human T cells. We and others have previously shown that T cells contribute to salt-sensitive 
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hypertension in rats and mice.1, 29 These conditions are associated with suppression of ang II 
production, indicating that this octapeptide is not needed for this action of immune cells in 
hypertension. Our results with pharmacological prevention of hypertension should be viewed 
with some caution however because pharmacologic agents can have off target effects that 
might directly inhibit T cell function. As an example, we previously showed that hydralazine 
potently inhibits the NADPH oxidase,30 and thus might prevent formation of immunogenic 
isoketal-protein adducts independent of its blood pressure lowering effects. To avoid the 
confounding effects of such agents, we examined the direct effect of ang II on both human T 
cells and human DCs however failed to observe a change in the production of inflammatory 
cytokines or the T regulatory cell transcription factor FoxP3. In preliminary experiments, we 
also found that norepinephrine did not enhance the ability of DCs to drive T cell proliferation.  
Taken together, we view these findings as suggesting that human immune cells likely take 
cues from other tissues in vivo to become activated in hypertension. In keeping with this, we 
recently found chronic vascular oxidative stress induces activation of both DCs and T cells in 
mice, likely by generating isoketals within the vessel that are taken up by DCs.31 It is possible 
therefore that vascular oxidative stress associated with hypertension promotes human T cell 
activation.  
We encountered several limitations in the present study that precluded in-depth study of these 
mice. We found that these mice did not tolerate the two surgeries needed for implantation of 
telemetry units for blood pressure measurement and subsequent osmotic minipump 
placement, and therefore relied upon tail cuff measurement of blood pressure. Our studies 
should also be interpreted with caution because it is unclear how effectively human T cell 
receptors interact with mouse adhesion molecules and chemokines. It is possible, for example, 
that vascular adhesion molecules in humans might more avidly attract activated T cells to 
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vessels than we observed in the humanized mouse. The humanized mouse also presents a 
limited window of time, ranging from 4 to 12 weeks after reconstitution with human tissues 
before graft vs. host disease develops, and therefore longer-term hypertensive challenges are 
problematic. In our studies, none of the mice exhibited signs of graft vs. host disease, such as 
weight loss, diarrhea or hair loss. Because human T cell expansion did not occur in the sham 
infused animals, we do not believe that the T cell activation observed in the ang II-treated 
group was due to graft vs. host disease. 
PERSPECTIVES 
This is the first study to demonstrate that human T cells respond to a hypertensive stimulus 
such as ang II by expanding and infiltrating the kidney and vasculature. Our results might also 
help explain the striking benefit of blood pressure correction observed in the recent SPRINT 
trial.32 It is conceivable that intensive blood pressure lowering by any means can prevent 
activation of human immune cells and therefore reduce cardiovascular inflammation.  
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NOVELTY AND SIGNIFICANCE 
 
1. What Is New? 
a. Ang II-induced hypertension leads to T cell activation in humanized mice.  
b. Humans with hypertension have an increase in the frequency of circulating 
memory T cells and an increase in the CD4+ T cells producing IL-17A and CD8+ 
T cells producing IFN-γ. 
2. What Is Relevant? 
a. Animal models have been used as surrogates to study hypertension in humans.  
b. Inflammation is a key component in experimental hypertension, and the current 
study shows that human cells are activated in the setting of Ang II-induced 
hypertension and in humans with hypertension.   
c. Correction of blood pressure prevented T cell accumulation in the kidney, aorta 
and lymph nodes of humanized mice.  
3. Summary 
a. Inflammation has been shown to play a key role in the promotion and 
maintenance of hypertension in experimental animals and has been indirectly 
implicated in human hypertension. We provide the first evidence that human T 
cells are activated by a hypertensive stimulus like angiotensin II. 
b. Phenotypic characterization of circulating T cells in humans might provide insight 
into immune activation in hypertension.  
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LEGENDS TO FIGURES 
Figure 1: Effects of hypertension on renal leukocyte and T cell infiltration. Humanized 
mice received sham or ang II infusion (490 ng/kg/min) for two weeks with or without co-
administration of hydralazine (Hyd) and hydrochlorothiazide (HCTZ). Single cell suspensions 
were prepared from kidneys of humanized mice and analyzed for total human leukocytes and 
T cells. Representative dot plots are of human live, singlets gated for (A) total leukocytes 
(CD45+), (B) total T cells (CD3+), (C) CD8+/CD4+ T cells. The solid black lines in the histogram 
indicate the gates used for analysis. Summary data are shown for renal accumulation of total 
leukocytes (D), total T cells (E), CD8+ T cells (F), and CD4+ T cells (G) in response to either a 
sham or ang II infusion. Data were analyzed using an unpaired T test or the non-parametric 
Mann Whitney test when variances between groups were not equal, n= 4-6 per group. 
Figure 2: Effects of hypertension on leukocyte and T cell infiltration into the 
descending, thoracic aorta. Mice underwent sham or Ang II infusion with or without co-
administration of hydralazine (Hyd) and hydrochlorothiazide (HCTZ) as in figure 1. 
Representative dot plots are shown of live, human, singlet cells gated for (A) total leukocytes 
(CD45+), (B) total T cells (CD3+), (C) CD8+/CD4+ T cells. Summary data are shown for aortic 
accumulation of total leukocytes (D), total T cells (E), CD8+ T cells (F) and CD4+ T cells (G) in 
response to either a sham or ang II infusion. Data were analyzed using an unpaired T test or 
the non-parametric Mann Whitney test when variances between groups were not equal, n= 4-6 
per group. 
Figure 3: Effect of hypertension on leukocyte and T cell infiltration into thoracic lymph 
nodes. Mice underwent sham or Ang II infusion with or without co-administration of 
hydralazine (Hyd) and hydrochlorothiazide (HCTZ) as in figure 1 and thoracic lymph nodes 
were harvested from the periaortic region. Representative images are of human live, singlets 
gated for (A) total leukocytes (CD45+), (B) total T cells (CD3+), (C) CD8+ / CD4+ T cells. The 
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solid black lines in the histogram indicate the gates that used for all of our analysis. Summary 
data are shown for the presence of total leukocytes (D), total T cells (E), CD8+ T cells (F), and 
CD4+ T cells (G). Data were analyzed using an unpaired T test or the non-parametric Mann 
Whitney test when variances between groups were not equal, n= 4-6 per group. 
Figure 4: Effect of hypertension on myeloid differentiation in the kidney, aorta and 
lymph nodes. Summary data from mice following sham or angiotensin II (ang II) infusion (490 
ng/kg/min) of non-CD3+ CD45+ cells in the kidney (A), descending, thoracic aorta (B), and 
thoracic lymph nodes (C). The flow cytometry gating strategy used to identify myeloid cells is 
shown (D). The kidney, aorta and lymph nodes of the humanized mice all showed 
differentiation of the monocytes to dendritic cells (E). Myeloid differentiation was not 
significantly shifted in any of the tissues when we compared monocyte (CD14+CD83-) vs. 
activated monocyte (CD14+CD83+) vs. dendritic cell (CD14-CD83+) populations.  
Figure 5: Direct effect of ang II on T cell phenotype and dendritic cell activation. Human 
T cells were cultured on anti-CD3 plates containing anti-DC28 (2 μg/ml) without and with ang II 
(0.1 μMol/L) for 7 days and intracellular staining was performed to detect the cytokines IFN-γ 
and IL-17A and the transcription factor FoxP3 (A-D). Human monocytes were differentiated 
into dendritic cells by exposure to GM-CSF and IL-4 for 7 days without and with ang II (0.1 
μMol/L). The differentiated DCs were then co-cultured with CFSE-labeled T cells from the 
same donor at a ratio of 1:10. Proliferation was measured by CFSE dilution (E). Isoketal-
protein adducts in DCs were determined by intracellular staining with isoketal adduct antibody 
D11 (F).  
Figure 6: Characterization of circulating T cells in humans with and without hypertension (n = 
20 for each). Blood was obtained from patients with hypertension (HTN) and normotensive 
controls (CTR) and T cells were stained for CD3, CD4, CD8 and the memory marker CD45RO 
(panels A and B). Intracellular staining was performed to identify cells producing IL-17A 
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(panels C and D) and for IFN-γ and TNFα (panel E and F). Data were analyzed using an 
unpaired T test with Bonferroni correction for multiple comparisons. 
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Table 1: Clinical characteristics of patients studied for circulating T cell phenotypes. 
Clinical features Control 
(n=20) 
Hypertension 
(n=20) 
p value 
Female sex (n; %) 11 (55%) 11 (55 %) NS 
Age (years ± SD) 52.6 ± 12 52.6 ± 11 NS 
BMI (kg/m2 ± SD) 28.2 ± 5.1 28.9 ± 5.1 NS 
Blood pressure characteristics    
Hypertension (%) 0% 100% <0.05 
Office blood pressure 126±13/83±8 150±19/90±11 <0.05 
24h ABPM (systolic mmHg ± SD) 120±13 143±18 <0.05 
24h ABPM (diastolic mmHg ± SD) 75±5 85±9 <0.05 
Renin (after supine position) 10.8±6 18±9 <0.05 
Aldosterone (after supine position) 126±30 230±150 <0.05 
Target organ characteristics    
GFR 74±14 78±12 NS 
Serum creatinine (μmol/L) 81±17 75 ± 24 NS 
LVEDV 103±26 110 ± 28 NS 
LVESV 41±15 34 ±11 NS 
EF 65±7 65±7 NS 
Cardiovascular risk 
characteristics 
   
Current Smoking (%) 2 (10%) 3 (15%) NS 
Ever smoking status (%) 8 (40%) 8 (40%) NS 
Glucose intolerance/DM 1 (5%) 5 (25%) NS 
Current blood glucose (mmol/L) 5.5±0.6 6.1±1.5 NS 
Total cholesterol (mmol/L) 5.7±1.0 4.9±1.7 NS 
Inflammatory/Autoimmune 
disease 
0 (0%) 0 (0%) NS 
hsCRP level 0.20±0.18 0.16±0.09 NS 
WBC (cells/mm3) 6.3±1.2 6.3±1.6 NS 
Atherosclerosis and CAD    
Ischemic heart disease (%) 2 (10%) 4 (20%) NS 
Prior myocardial infarction (%) 0 (0%) 3 (15%) NS 
Peripheral Arterial Disease (%) 0 (0%) 0 (0%) NS 
Stroke/TIA 0 (0%) 0 (0%) NS 
PAD 0 (0%) 0 (0%) NS 
Medications    
ACE inhibitors (%) 0 (0%) 9 (45%)  
Angiotensin Receptor Blockers 
(%) 
0 (0%) 6 (30%)  
Beta – blockers (%) 0 (0%) 12 (60%)  
Calcium channel blockers (%) 0 (0%) 14 (70%)  
Alpha – blockers (%) 0 (0%) 6 (30%)  
Diuretics (%) 0 (0%) 9 (45%)  
Statins (%) 1 (5%) 9 (45%)  
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Table 2: Effect of ang II and ang II + anti-hypertensive treatment on accumulation of human 
memory (CD45RO+) cells. 
 CD3 CD4 CD8 
 Sham  Ang II Ang II 
Hyd + 
HCTZ 
Sham Ang II Ang II 
Hyd + 
HCTZ 
Sham  Ang 
II 
Ang II 
Hyd + 
HCTZ 
Kidney 1443 
±295 
6600 
±2923* 
1227  
±661† 
1266 ± 
227 
6057  
±2791*
1161 
±633 
337 
±57 
674 
±246
4 
± 3† 
          
Aorta 113  
±19 
333  
±116 * 
194  
±63† 
93  
±16 
294 
 ±105* 
181  
±58 
29  
±7 
44  
±12 
15  
±4† 
          
Lymph 
Nodes 
443  
±233 
2642 
±712* 
17736  
±10333† 
350 
±181 
2258  
±603* 
16638 
±9470† 
71  
±34 
276 
±79 
145  
±90 
N = 4-6 per group, * p < 0.05 vs sham. † p < 0.05 vs ang II. Hyd = hydralazine. HCTZ = 
hydrochlorothiazide 
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